Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese.
Adolescent
Adult
Aged
Biomarkers
/ blood
Blood Glucose
/ drug effects
Cerebrovascular Disorders
/ diagnosis
Databases, Factual
Diabetes Mellitus
/ blood
Glycated Hemoglobin
/ metabolism
Glycemic Control
Humans
Hypoglycemic Agents
/ therapeutic use
Incidence
Japan
/ epidemiology
Male
Middle Aged
Prognosis
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Young Adult
Borderline glycemia
Cerebrovascular disease
Diabetes mellitus
Epidemiology
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
03 09 2021
03 09 2021
Historique:
received:
28
06
2021
accepted:
20
08
2021
entrez:
4
9
2021
pubmed:
5
9
2021
medline:
8
2
2022
Statut:
epublish
Résumé
Although both a history of cerebrovascular disease (CVD) and glucose abnormality are risk factors for CVD, few large studies have examined their association with subsequent CVD in the same cohort. Thus, we compared the impact of prior CVD, glucose status, and their combinations on subsequent CVD using real-world data. This is a retrospective cohort study including 363,627 men aged 18-72 years followed for ≥ 3 years between 2008 and 2016. Participants were classified as normoglycemia, borderline glycemia, or diabetes defined by fasting plasma glucose, HbA1c, and antidiabetic drug prescription. Prior and subsequent CVD (i.e. ischemic stroke, transient ischemic attack, and non-traumatic intracerebral hemorrhage) were identified according to claims using ICD-10 codes, medical procedures, and questionnaires. Participants' mean age was 46.1 ± 9.3, and median follow up was 5.2 (4.2, 6.7) years. Cox regression analysis showed that prior CVD + conferred excess risk for CVD regardless of glucose status (normoglycemia: hazard ratio (HR), 8.77; 95% CI 6.96-11.05; borderline glycemia: HR, 7.40, 95% CI 5.97-9.17; diabetes: HR, 5.73, 95% CI 4.52-7.25). Compared with normoglycemia, borderline glycemia did not influence risk of CVD, whereas diabetes affected subsequent CVD in those with CVD- (HR, 1.50, 95% CI 1.34-1.68). In CVD-/diabetes, age, current smoking, systolic blood pressure, high-density lipoprotein cholesterol, and HbA1c were associated with risk of CVD, but only systolic blood pressure was related to CVD risk in CVD + /diabetes. Prior CVD had a greater impact on the risk of CVD than glucose tolerance and glycemic control. In participants with diabetes and prior CVD, systolic blood pressure was a stronger risk factor than HbA1c. Individualized treatment strategies should consider glucose tolerance status and prior CVD.
Sections du résumé
BACKGROUND
Although both a history of cerebrovascular disease (CVD) and glucose abnormality are risk factors for CVD, few large studies have examined their association with subsequent CVD in the same cohort. Thus, we compared the impact of prior CVD, glucose status, and their combinations on subsequent CVD using real-world data.
METHODS
This is a retrospective cohort study including 363,627 men aged 18-72 years followed for ≥ 3 years between 2008 and 2016. Participants were classified as normoglycemia, borderline glycemia, or diabetes defined by fasting plasma glucose, HbA1c, and antidiabetic drug prescription. Prior and subsequent CVD (i.e. ischemic stroke, transient ischemic attack, and non-traumatic intracerebral hemorrhage) were identified according to claims using ICD-10 codes, medical procedures, and questionnaires.
RESULTS
Participants' mean age was 46.1 ± 9.3, and median follow up was 5.2 (4.2, 6.7) years. Cox regression analysis showed that prior CVD + conferred excess risk for CVD regardless of glucose status (normoglycemia: hazard ratio (HR), 8.77; 95% CI 6.96-11.05; borderline glycemia: HR, 7.40, 95% CI 5.97-9.17; diabetes: HR, 5.73, 95% CI 4.52-7.25). Compared with normoglycemia, borderline glycemia did not influence risk of CVD, whereas diabetes affected subsequent CVD in those with CVD- (HR, 1.50, 95% CI 1.34-1.68). In CVD-/diabetes, age, current smoking, systolic blood pressure, high-density lipoprotein cholesterol, and HbA1c were associated with risk of CVD, but only systolic blood pressure was related to CVD risk in CVD + /diabetes.
CONCLUSIONS
Prior CVD had a greater impact on the risk of CVD than glucose tolerance and glycemic control. In participants with diabetes and prior CVD, systolic blood pressure was a stronger risk factor than HbA1c. Individualized treatment strategies should consider glucose tolerance status and prior CVD.
Identifiants
pubmed: 34479567
doi: 10.1186/s12933-021-01367-7
pii: 10.1186/s12933-021-01367-7
pmc: PMC8417951
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
hemoglobin A1c protein, human
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
174Informations de copyright
© 2021. The Author(s).
Références
J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):368-72
pubmed: 15716529
J Am Heart Assoc. 2018 May 17;7(11):
pubmed: 29773578
BMJ. 2016 Nov 23;355:i5953
pubmed: 27881363
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
N Engl J Med. 2018 Dec 20;379(25):2429-2437
pubmed: 30575491
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
Arch Phys Med Rehabil. 1995 May;76(5):399-405
pubmed: 7741608
Eur J Health Econ. 2019 Feb;20(1):107-134
pubmed: 29909569
Obes Res Clin Pract. 2014 Sep-Oct;8(5):e466-75
pubmed: 25263836
Neurology. 2021 Jan 5;96(1):e54-e66
pubmed: 33046613
Cardiovasc Diabetol. 2020 Mar 30;19(1):41
pubmed: 32228577
J Stroke Cerebrovasc Dis. 2012 May;21(4):245-53
pubmed: 22365283
BMJ. 2020 Jul 15;370:m2297
pubmed: 32669282
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Diabetes Metab. 2017 Jun;43(3):261-264
pubmed: 27712966
Cardiovasc Diabetol. 2020 Aug 8;19(1):125
pubmed: 32771014
Lancet. 1998 Jun 13;351(9118):1755-62
pubmed: 9635947
Lancet. 2009 Nov 14;374(9702):1677-86
pubmed: 19878986
Stroke. 2014 Dec;45(12):3754-832
pubmed: 25355838
Eur J Prev Cardiol. 2019 Jul;26(10):1080-1091
pubmed: 30862232
Stroke. 2011 Dec;42(12):3347-51
pubmed: 21998054
Metabolism. 2008 Mar;57(3):333-8
pubmed: 18249204
J Stroke Cerebrovasc Dis. 2015 Sep;24(9):1961-8
pubmed: 26166420
N Engl J Med. 2003 Jan 30;348(5):383-93
pubmed: 12556541
N Engl J Med. 1998 Jul 23;339(4):229-34
pubmed: 9673301
BMC Med. 2019 Jul 12;17(1):136
pubmed: 31296205
Am J Med. 2017 Jun;130(6):707-719.e8
pubmed: 28109971
Lancet. 1998 Sep 12;352(9131):854-65
pubmed: 9742977
Stroke. 2011 May;42(5):1489-94
pubmed: 21454819
Diabetologia. 2019 Sep;62(9):1575-1580
pubmed: 31154479
Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964
pubmed: 29079252
Stroke. 2021 Jul;52(7):e364-e467
pubmed: 34024117
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5084-5090
pubmed: 30994885
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334
Metabolism. 2019 Dec;101:153991
pubmed: 31666194
Stroke. 2007 Apr;38(4):1154-60
pubmed: 17332448
N Engl J Med. 2013 Jul 11;369(2):145-54
pubmed: 23796131
BMJ. 2012 Jun 07;344:e3564
pubmed: 22677795
Biomed Pharmacother. 2021 Jan;133:111066
pubmed: 33378967
JAMA Neurol. 2019 Nov 1;76(11):1309-1318
pubmed: 31355878
Int J Stroke. 2014 Oct;9(7):873-8
pubmed: 24148608
Cardiovasc Diabetol. 2020 May 6;19(1):53
pubmed: 32375783
Eur J Epidemiol. 2001;17(12):1097-104
pubmed: 12530768
Diabetes Care. 2015 Oct;38(10):1930-6
pubmed: 26307606
Arch Intern Med. 2011 Aug 8;171(15):1352-60
pubmed: 21824948
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
Pharmacoepidemiol Drug Saf. 2021 May;30(5):594-601
pubmed: 33629363
BMJ. 1998 Sep 12;317(7160):703-13
pubmed: 9732337